Clinical Trial Update: Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03) [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial is evaluating chemotherapy in combination with anlotinib and Benmelstobart for HR+/HER2- breast cancer; the study is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Benmelstobart

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: HR+/HER2- Breast Cancer | Phase 2 | Status: RECRUITING